Compare TRDA & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRDA | AGMB |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | 62 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.7M | 562.4M |
| IPO Year | 2021 | N/A |
| Metric | TRDA | AGMB |
|---|---|---|
| Price | $7.08 | $11.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $21.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 677.8K | 53.8K |
| Earning Date | 05-08-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,421,000.00 | N/A |
| Revenue This Year | $39.97 | N/A |
| Revenue Next Year | $50.80 | $17.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.93 | $9.00 |
| 52 Week High | $16.45 | $17.45 |
| Indicator | TRDA | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 37.64 | 50.03 |
| Support Level | $5.75 | $10.17 |
| Resistance Level | $7.54 | $12.29 |
| Average True Range (ATR) | 0.50 | 0.76 |
| MACD | 0.10 | 0.05 |
| Stochastic Oscillator | 76.46 | 52.12 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.